Alpha 1 抗胰蛋白酶缺乏症治疗市场报告（按治疗类型、给药途径、最终用户和地区划分）2025 年至 2033 年

2024 年全球 α1 抗胰蛋白酶缺乏症治疗市场规模达 22 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 42 亿美元，2025-2033 年期间的成长率 (CAGR) 为 7.22%。

α-1 抗胰蛋白酶 (AAT) 缺乏症是一种遗传性疾病，会导致人体无法产生足够的 AAT 蛋白。 AAT 蛋白对于保护肺部和肝臟免受体内其他蛋白质的不良影响至关重要。严重 AAT 缺乏症患者可能发展为肝硬化、慢性阻塞性肺病 (COPD) 和肺气肿。此病可透过基因检测或血液检测进行诊断。一些治疗方法包括强化治疗、肺部復健和氧气治疗，这些疗法使用支气管扩张剂和皮质类固醇等药物，这些药物可以静脉注射或吸入。

呼吸系统疾病盛行率的上升是推动市场成长的关键因素之一。此外，增强疗法的广泛应用也为市场成长提供了动力。此疗法从健康捐赠者的血浆中提取AAT蛋白，以提高患者呼吸道中的AAT水平。同时，该疗法也能延缓肺气肿的进展，最大限度地减少病情发作的频率，并加快康復速度，促使其越来越受到患者和医护人员的青睐。此外，诊断方法的各项技术进步以及AAT生产和纯化创新製程的开发，也是其他促进成长的因素。这些产品的品质得到了提升，并且不含病毒和细菌等污染物。其他因素，包括广泛的研发活动以及医疗基础设施的改善，预计将进一步推动市场成长。

本报告回答的关键问题

• α1抗胰蛋白酶缺乏症治疗市场有多大？ α1抗胰蛋白酶缺乏症治疗市场的未来前景如何？
• 推动 α1 抗胰蛋白酶缺乏症治疗市场发展的关键因素有哪些？
• 哪个地区占据最大的 α1 抗胰蛋白酶缺乏症治疗市场份额？
• 全球 α1 抗胰蛋白酶缺乏症治疗市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 次要来源
• 市场评估
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章：执行摘要

第四章：简介

第五章：全球 Alpha 1 抗胰蛋白酶缺乏症治疗市场

• 市场概览
• 市场表现
• COVID-19的影响
• 市场预测

第六章：市场区隔：依治疗类型

• 增强疗法
• 支气管扩张剂
• 皮质类固醇
• 氧气疗法
• 其他的

第七章：市场区隔：依行政途径

• 肠外
• 吸入
• 口服

第八章：市场区隔：按最终用户

• 医院
• 专科诊所
• 其他的

第九章：市场细分：依地区

• 北美洲
  • 美国
  • 加拿大
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他的
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他的
• 中东和非洲

第十章：SWOT分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • AstraZeneca PLC
  • CH Boehringer Sohn AG & Ko. KG
  • CSL Limited
  • GlaxoSmithKline Plc
  • Grifols SA
  • Kamada Ltd.
  • LFB Biomedicaments SA
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

The global alpha 1 antitrypsin deficiency treatment market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.

Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.

The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Treatment Type:

• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy
• Others

Breakup by Route of Administration:

• Parenteral
• Inhalation
• Oral

Breakup by End User:

• Hospitals
• Specialty Clinics
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1.How big is the alpha 1 antitrypsin deficiency treatment market?
• 2.What is the future outlook of alpha 1 antitrypsin deficiency treatment market?
• 3.What are the key factors driving the alpha 1 antitrypsin deficiency treatment market?
• 4.Which region accounts for the largest alpha 1 antitrypsin deficiency treatment market share?
• 5.Which are the leading companies in the global alpha 1 antitrypsin deficiency treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Alpha 1 Antitrypsin Deficiency Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Treatment Type

• 6.1 Augmentation Therapy
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Bronchodilators
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Corticosteroids
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Oxygen Therapy
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Parenteral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Inhalation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Oral
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Specialty Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AstraZeneca PLC
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 C.H. Boehringer Sohn AG & Ko. KG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 CSL Limited
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 GlaxoSmithKline Plc
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Grifols S.A.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Kamada Ltd.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 LFB Biomedicaments S.A.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Takeda Pharmaceutical Company Limited
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Teva Pharmaceutical Industries Ltd.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio

List of Figures

• Figure 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Major Drivers and Challenges
• Figure 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Treatment Type (in %), 2024
• Figure 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Route of Administration (in %), 2024
• Figure 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by End User (in %), 2024
• Figure 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Region (in %), 2024
• Figure 8: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: North America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: North America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: United States: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: United States: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: China: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: China: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: India: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: India: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: France: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: France: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 78: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: SWOT Analysis
• Figure 79: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Value Chain Analysis
• Figure 80: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
• Table 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
• Table 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Structure
• Table 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Players